Nothing Special   »   [go: up one dir, main page]

WO2023204603A1 - Composition for preventing, alleviating, or treating coronavirus infection, containing medicinal herb complex extract as active ingredient - Google Patents

Composition for preventing, alleviating, or treating coronavirus infection, containing medicinal herb complex extract as active ingredient Download PDF

Info

Publication number
WO2023204603A1
WO2023204603A1 PCT/KR2023/005308 KR2023005308W WO2023204603A1 WO 2023204603 A1 WO2023204603 A1 WO 2023204603A1 KR 2023005308 W KR2023005308 W KR 2023005308W WO 2023204603 A1 WO2023204603 A1 WO 2023204603A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
parts
coronavirus
composition
extract
Prior art date
Application number
PCT/KR2023/005308
Other languages
French (fr)
Korean (ko)
Inventor
권선오
진영희
이상명
김상현
윤지원
Original Assignee
한국 한의학 연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국 한의학 연구원 filed Critical 한국 한의학 연구원
Publication of WO2023204603A1 publication Critical patent/WO2023204603A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/346—Platycodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/532—Agastache, e.g. giant hyssop
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535—Perilla (beefsteak plant)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888—Pinellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto

Definitions

  • the present invention relates to a composition for preventing, improving, or treating coronavirus infection comprising a complex herbal medicine extract, particularly an extract of Gwakhyangjeonggisan, as an active ingredient.
  • the new type 2 severe acute respiratory syndrome coronavirus (SARS-CoV2) is a virus that has a single-stranded positive RNA genome consisting of approximately 30,000 base pairs, and the viral surface is surrounded by an envelope. Since it was first reported in Wuhan, China at the end of December 2019, the number of infected people has rapidly increased worldwide. The virus spreads so efficiently between people that the World Health Organization has declared it a pandemic with the potential to spread around the world and is seeking responses.
  • Typical Covid-19 patients show relatively mild symptoms such as increased body temperature, cough, and chest pain, but some patients develop serious diseases such as difficulty breathing and pneumonia, leading to death.
  • coronavirus infections include ribavirin, famciclovir, nitazoxanide, nafamostat, and chloroquine.
  • Remdesi Remdesivir (GS-5734) and favipiravir are being used to treat coronavirus infections, but their effectiveness is low and the incidence of variant viruses is high due to the nature of nucleic acid analog antivirals, so two or more types of antivirals are applied together. .
  • Most antiviral drugs used for coronavirus infections have the ability to inhibit RNA polymerase, but mouse hepatitis virus, a type of coronavirus that is resistant to remdesivir, has been discovered, and existing antiviral drugs have been discovered. Viral drugs are ineffective.
  • antiviral drugs developed to date have severe side effects, so great caution is required in their application.
  • Korean Patent Publication No. 2022-0013625 discloses an anti-coronavirus composition characterized by containing an extract of Ulgoebul tree as an active ingredient
  • Korean Patent Publication No. 2022-0018953 discloses an anti-coronavirus composition containing fern extract or a fraction thereof.
  • the present invention was developed in response to the above-mentioned needs, and provides an antiviral composition for coronavirus containing an extract of Gwakhyangjeonggisan as an active ingredient, wherein the extract protects cells from coronavirus infection and inhibits virus proliferation.
  • the present invention was completed by confirming that it inhibits and reduces the mortality rate due to infection in a coronavirus infection animal model.
  • the present invention provides an antiviral composition for coronavirus containing an extract of Kwak Hyangjeonggi acid as an active ingredient.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of coronavirus infection containing Kwakhyangjeonggisan extract as an active ingredient.
  • the present invention provides a health functional food composition for preventing or improving coronavirus infection containing Kwak Hyangjeonggi acid extract as an active ingredient.
  • the present invention provides a quasi-drug composition for preventing or improving coronavirus infection, comprising an extract of Kwakhyangjeonggi acid as an active ingredient.
  • the present invention provides a cosmetic composition for preventing or improving coronavirus infection containing Kwak Hyangjeonggi acid extract as an active ingredient.
  • the present invention provides a feed additive for preventing or improving coronavirus infection containing Kwakhyangjeonggisan extract as an active ingredient.
  • the present invention relates to a composition for preventing, ameliorating or treating coronavirus infection comprising an extract of Kwak Hyang Jeong Gi Acid as an active ingredient.
  • the extract of Kwak Hyang Jeong Gi Acid protects cells from coronavirus infection, inhibits the proliferation of viruses, and prevents the spread of coronavirus. It is effective in reducing the mortality rate due to infection in animal models of viral infection.
  • Figure 1 shows the results of confirming the antiviral effect of Kwak Hyangjeonggi acid extract against SARS-CoV2 through CPE (Cytopathic effect) inhibition analysis.
  • (A) is the result of quantifying the antiviral effect against SARS-CoV2 according to treatment with Gwakhyangjeonggisan extract at each concentration
  • (B) is the result of quantifying the antiviral effect against SARS-CoV2 according to treatment with remdesivir, a positive control. This is one result.
  • NC is the normal group
  • VC is the control group treated with SARS-CoV2.
  • Figure 2 is a fluorescence photograph (A) confirming the viral infection inhibition effect of Kwak Hyangjeonggi acid extract on SARS-CoV2 and the result of quantifying it (B).
  • NC is the normal group
  • VC is the control group treated with SARS-CoV2.
  • Figure 3 shows the results of confirming body weight (A), body temperature (B), and survival rate (C) according to administration of Gwakhyangjeonggisan extract in a SARS-CoV2 infection animal model.
  • Mock is a normal group not infected with SARS-CoV2
  • Control is a SARS-CoV2 infected group.
  • the present invention provides an antiviral composition for coronavirus containing an extract of Kwak Hyangjeonggi acid as an active ingredient.
  • the coronavirus may be one or more types selected from the group consisting of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2), severe acute respiratory syndrome coronavirus (SARS CoV), and Middle East respiratory syndrome (MERS) coronavirus, Preferably, it is type 2 severe acute respiratory syndrome coronavirus (SARS-CoV2), but is not limited thereto.
  • SARS-CoV2 severe acute respiratory syndrome coronavirus
  • SARS CoV severe acute respiratory syndrome coronavirus
  • SARS CoV severe acute respiratory syndrome coronavirus
  • MERS Middle East respiratory syndrome
  • the extraction solvent of the Kwak Hyangjeonggi acid extract is preferably water, a lower alcohol of C 1 to C 4 or a mixture thereof, more preferably water, but is not limited thereto.
  • the Kwakhyangjeonggisan may be a mixture of Kwakhyang, perilla leaf, Baekji, Daebokpi, Bokryeong, Hubak, Baekchul, Jinpi, Banha, Gilgyeong, Perilla, ginger and jujube, preferably 150 ⁇ 250 parts by weight of Gwakhyang, 80 ⁇ 170 parts by weight of perilla leaf, 50 ⁇ 80 parts by weight of Baekji, 50 ⁇ 80 parts by weight of Daebokpi, 50 ⁇ 80 parts by weight of Bokryeong, 50 ⁇ 80 parts by weight of Hubak, 50 ⁇ 80 parts by weight of Baekchul, It may be a mixture of 50 to 80 parts by weight of dermis, 50 to 80 parts by weight of Banha, 50 to 80 parts by weight of Gilt, 50 to 80 parts by weight of perilla root, 30 to 70 parts by weight of ginger and 50 to 90 parts by weight of jujube, and is more preferred.
  • the extract of Kwak Hyangjeonggi acid of the present invention has the effect of inhibiting the proliferation of type 2 severe acute respiratory syndrome coronavirus.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of coronavirus infection containing Kwakhyangjeonggisan extract as an active ingredient.
  • the pharmaceutical composition according to the present invention can be formulated and used in the form of oral dosage forms such as capsules, powders, granules, tablets, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions according to conventional methods. You can.
  • the pharmaceutical composition according to the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent.
  • Carriers, excipients and diluents that may be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate. , cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. in the pharmaceutical composition. It is prepared by mixing. Additionally, in addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, oral solutions, emulsions, syrups, etc.
  • Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
  • Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate.
  • As a base for suppositories wethepsol, macrogol, Tween 61, cacao, laurin, glycerogelatin, etc. can be used.
  • the appropriate dosage of the pharmaceutical composition of the present invention may be prescribed in various ways depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity. You can.
  • the pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, it can be administered topically on the skin, intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc.
  • the present invention provides a health functional food composition for preventing or improving coronavirus infection containing Kwak Hyangjeonggi acid extract as an active ingredient.
  • composition may be manufactured in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup, and beverage, but is not limited thereto.
  • the health functional food composition of the present invention When using the health functional food composition of the present invention as a food additive, the health functional food composition may be added as is or used together with other foods or food ingredients, and may be used appropriately according to conventional methods.
  • the amount of active ingredient can be appropriately used depending on the purpose of use (prevention or improvement).
  • the health functional food composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the total raw materials.
  • the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
  • Health functional foods There are no particular restrictions on the types of health functional foods. Examples of foods to which the health functional food composition can be added include meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, and tea. There are drinks, alcoholic beverages, and vitamin complexes, and it includes all health foods in the conventional sense.
  • the health functional food composition of the present invention can be manufactured into food, especially functional food.
  • the functional food of the present invention includes ingredients commonly added during food production, and includes, for example, proteins, carbohydrates, fats, nutrients and seasonings.
  • ingredients commonly added during food production includes, for example, proteins, carbohydrates, fats, nutrients and seasonings.
  • natural carbohydrates or flavoring agents may be included as additional ingredients in addition to the active ingredient.
  • the natural carbohydrates include monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g., dextrins, cyclodextrins, etc.), or sugar alcohols (e.g., For example, xylitol, sorbitol, erythritol, etc.) is preferable.
  • the flavoring agent may be a natural flavoring agent (e.g., thaumatin, stevia extract, etc.) or a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).
  • the ratio of the ingredients added is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food composition of the present invention.
  • the present invention provides a quasi-drug composition for preventing or improving coronavirus infection, comprising an extract of Kwakhyangjeonggi acid as an active ingredient.
  • the quasi-drugs may include external skin preparations and personal hygiene products.
  • it may be a disinfectant cleaner, shower foam, garnish, wet tissue, detergent soap, hand wash, or ointment, but is not limited thereto.
  • the composition can be added as is or used with other quasi-drugs or quasi-drug components, and can be used appropriately according to conventional methods.
  • the mixing amount of the active ingredient can be appropriately determined depending on the purpose of use.
  • the quasi-drug composition of the present invention may be manufactured in the form of a general emulsified formulation or solubilized formulation.
  • it may have a formulation such as lotion, cream, ointment, spray, oil gel, gel, oil, or aerosol, but can be used without limitation as long as it shows the effect of preventing or improving the coronavirus infection of the present invention. there is.
  • the quasi-drug composition contains oil, water, surfactants, moisturizers, lower alcohols with 1 to 4 carbon atoms, thickeners, chelating agents, colorants, preservatives or fragrances, etc., which are generally mixed in quasi-drug compositions, as appropriate for each dosage form. Can be used in combination.
  • the present invention provides a cosmetic composition for preventing or improving coronavirus infection containing Kwak Hyangjeonggi acid extract as an active ingredient.
  • the cosmetic composition of the present invention includes ingredients commonly used in cosmetic compositions, such as antioxidants, stabilizers, solubilizers, vitamins, conventional auxiliaries such as pigments and fragrances, and carriers.
  • the cosmetic composition of the present invention can be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing products. , oil, powder foundation, emulsion foundation, wax foundation, spray, etc., but is not limited thereto. More specifically, it can be manufactured in the form of flexible lotion (skin), nourishing lotion (milk lotion), nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, shampoo, pack, spray or powder. You can.
  • the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacantha, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier ingredients. It can be.
  • the formulation of the present invention is a powder or spray
  • lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder can be used as the carrier ingredient.
  • chlorofluorohydrocarbon and propane may be used as carrier ingredients.
  • May contain propellants such as butane or dimethyl ether.
  • a solvent, solubilizing agent, or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 , 3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan.
  • the carrier ingredients include water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, and microcrystals.
  • a liquid diluent such as ethanol or propylene glycol
  • a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester
  • microcrystals ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester
  • Cellulose, aluminum metahydroxide, bentonite, agar or tragacantha can be used.
  • the carrier ingredients include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, and fatty acid amide.
  • Ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester can be used.
  • the present invention provides a feed additive for preventing or improving coronavirus infection containing Kwakhyangjeonggisan extract as an active ingredient.
  • the feed additive of the present invention corresponds to supplementary feed under the Feed Management Act.
  • the term 'feed' may mean any natural or artificial diet, meal, etc., or a component of the meal, for or suitable for eating, ingestion, and digestion by animals.
  • the type of feed is not particularly limited, and feed commonly used in the art can be used.
  • Non-limiting examples of the feed include plant feeds such as grains, roots and fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils and fats, starches, cucurbits or grain by-products;
  • animal feeds such as proteins, inorganic substances, fats and oils, minerals, oils and fats, single-cell proteins, zooplanktons or food. These may be used alone or in combination of two or more types.
  • Gwakhyangjeonggisan extract of the present invention used in the extract of Gwakhyangjeonggisan, Gwakhyang, perilla leaf, Baekji, Daebokpi, Bokryeong, Hubak, Baekchul, Jinpi, Banha, Gilgyeong, Perilla perilla, ginger and jujube were purchased as standard products from Dongwoodang Pharmaceutical, weighing 189.1g.
  • the Kwakhyangjeonggi acid extract of the present invention protects cells from the SARS-CoV2 virus and kills the virus.
  • the antiviral effect of inhibiting proliferation was excellent.
  • Vero E6 cells were distributed in a 96 -well plate at 1 SARS-CoV2 diluted 1000 times with DMEM was treated and then cultured for 24 hours. After incubation, the cells were fixed with a 4% (v/v) formaldehyde solution, reacted with a primary antibody (N-protein) diluted 2000 times, and then reacted with a secondary antibody diluted 200 times. After the reaction, the cells were observed under a fluorescence microscope, and the fluorescence intensity was analyzed.
  • the body weight of the group administered the Kwak Hyangjeonggi acid extract of the present invention was slightly increased compared to the SARS-CoV2 infection group after the 6th day, and the body temperature of the SARS-CoV2 infection group was 6 days.
  • the group administered the Kwak Hyang Jeong-ki acid extract of the present invention maintained body temperature at a level similar to that of the normal group, and the survival rate of the SARS-CoV2 infection group on day 10 decreased sharply, but the The survival rate of the extract administered group was maintained at about 60%. Therefore, it was determined that the Kwak Hyangjeonggi acid extract of the present invention can reduce the mortality rate of the severe SARS-CoV2 infection group.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a composition for preventing, alleviating or treating coronavirus infection, containing a Gwakhyanggunggi-san extract as an active ingredient. The Gwakhyangjeonggi-san extract has the excellent effects of protecting cells from coronavirus infection, inhibiting the proliferation of viruses and reducing the mortality rate caused by infection in animal models infected with coronavirus, and thus the composition of the present invention, comprising the Gwakhyangjeonggi-san extract as an active ingredient, can be effectively used as an agent for treating coronavirus infection, an anti-coronavirus health functional food, quasi-drug, cosmetic product, or feed additive.

Description

복합한약재 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물Composition for preventing, improving or treating coronavirus infection containing extract of complex herbal medicine as an active ingredient
본 발명은 복합한약재 추출물, 특히 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing, improving, or treating coronavirus infection comprising a complex herbal medicine extract, particularly an extract of Gwakhyangjeonggisan, as an active ingredient.
본 결과물은 과학기술정보통신부의 한국한의학연구원연구운영비지원(R＆D) 사업의 지원을 받아 수행되었습니다(과제번호: 1711175247).This work was carried out with support from the Korea Institute of Oriental Medicine Research and Operational Expenses (R&D) Project of the Ministry of Science and ICT (Project Number: 1711175247).
신종 제2형 중증급성호흡기증후군 코로나바이러스(SARS-CoV2)는 약 3만 개의 염기쌍으로 이루어진 단일 가닥의 양성 RNA 게놈을 가지고 있고, 바이러스 표면이 외피로 둘러싸여 있는 바이러스이다. 2019년 12월 말에 중국 우한에서 최초로 보고된 후 전 세계적으로 감염자가 폭증하였다. 상기 바이러스는 사람 사이의 전파가 매우 효율적으로 이루어져 세계보건기구에서도 전 세계에 유행이 가능한 펜데믹으로 선포하고 대응을 모색하고 있다.The new type 2 severe acute respiratory syndrome coronavirus (SARS-CoV2) is a virus that has a single-stranded positive RNA genome consisting of approximately 30,000 base pairs, and the viral surface is surrounded by an envelope. Since it was first reported in Wuhan, China at the end of December 2019, the number of infected people has rapidly increased worldwide. The virus spreads so efficiently between people that the World Health Organization has declared it a pandemic with the potential to spread around the world and is seeking responses.
일반적인 코비드-19 환자는 체온상승, 기침 및 가슴 통증과 같은 비교적 심하지 않은 증상을 보이지만, 일부 환자에게서는 호흡곤란 및 폐렴과 같은 심각한 질환으로 발전되어 사망에 이르게 된다. Typical Covid-19 patients show relatively mild symptoms such as increased body temperature, cough, and chest pain, but some patients develop serious diseases such as difficulty breathing and pneumonia, leading to death.
현재까지 코로나바이러스 감염증에 대해 공인된 치료제로는 리바비린(ribavirin), 팜시클로비르(famciclovir), 니타족사나이드(nitazoxanide), 나파모스타트(nafamostat) 및 클로로퀸(chloroquine) 등이 알려져 있으며, 이외에도 렘데시비르(remdesivir, GS-5734)와 파비피라비르(favipiravir)가 코로나바이러스 감염증 치료에 사용되고 있으나, 효과가 낮고 핵산 아날로그형 항바이러스제들의 특성상 변종바이러스의 발생율이 높아 2종 이상의 항바이러스제를 같이 적용하고 있다. 코로나바이러스 감염증에 사용되는 항바이러스제들은 대부분 RNA 폴리머라아제(polymerase) 억제능을 가지고 있지만, 렘데시비르에 대한 내성을 가지는 코로나바이러스의 일종인 마우스 간염 바이러스(Mouse hepatitis virus)가 발견되었으며, 기존의 항바이러스제의 효과가 없는 실정이다. 또한, 현재까지 개발된 항바이러스제들은 심한 부작용을 나타내고 있으므로, 그 응용에 있어서 많은 주의가 필요하다. To date, recognized treatments for coronavirus infections include ribavirin, famciclovir, nitazoxanide, nafamostat, and chloroquine. In addition, Remdesi Remdesivir (GS-5734) and favipiravir are being used to treat coronavirus infections, but their effectiveness is low and the incidence of variant viruses is high due to the nature of nucleic acid analog antivirals, so two or more types of antivirals are applied together. . Most antiviral drugs used for coronavirus infections have the ability to inhibit RNA polymerase, but mouse hepatitis virus, a type of coronavirus that is resistant to remdesivir, has been discovered, and existing antiviral drugs have been discovered. Viral drugs are ineffective. In addition, antiviral drugs developed to date have severe side effects, so great caution is required in their application.
또한, 현재 가장 일반적인 치료 방법은 증상을 완화하는 대증요법이다. 따라서 코로나바이러스의 발생을 예방하고 치료하기 위한 감염 억제 효과가 뛰어나고 독성이 적은 새로운 항코로나바이러스제의 개발 필요성이 증가되고 있다.Additionally, currently the most common treatment method is symptomatic therapy to relieve symptoms. Therefore, the need to develop new anti-coronavirus drugs with excellent infection control effects and low toxicity to prevent and treat coronavirus outbreaks is increasing.
한편, 한국공개특허 제2022-0013625호에는 울괴불나무 추출물을 유효성분으로 포함하는 것을 특징으로 하는 항코로나바이러스 조성물이 개시되어 있고, 한국공개특허 제2022-0018953호에는 고사리 추출물 또는 이의 분획물을 포함하는 항바이러스용 조성물이 개시되어 있지만, 본 발명의 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물에 관해 전혀 개시된 바 없다. Meanwhile, Korean Patent Publication No. 2022-0013625 discloses an anti-coronavirus composition characterized by containing an extract of Ulgoebul tree as an active ingredient, and Korean Patent Publication No. 2022-0018953 discloses an anti-coronavirus composition containing fern extract or a fraction thereof. Although an antiviral composition has been disclosed, there has been no disclosure at all regarding a composition for preventing, improving, or treating coronavirus infection containing the extract of Gwakhyangjeonggi acid of the present invention as an active ingredient.
본 발명은 상기와 같은 요구에 의해 도출된 것으로, 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스에 대한 항바이러스용 조성물을 제공하고, 상기 추출물이 코로나바이러스 감염으로부터 세포를 보호하고, 바이러스 증식을 억제하며, 코로나바이러스 감염 동물모델에서 감염에 의한 치사율을 감소시키는 것을 확인함으로써, 본 발명을 완성하였다.The present invention was developed in response to the above-mentioned needs, and provides an antiviral composition for coronavirus containing an extract of Gwakhyangjeonggisan as an active ingredient, wherein the extract protects cells from coronavirus infection and inhibits virus proliferation. The present invention was completed by confirming that it inhibits and reduces the mortality rate due to infection in a coronavirus infection animal model.
상기 과제를 해결하기 위하여, 본 발명은 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스에 대한 항바이러스용 조성물을 제공한다. In order to solve the above problems, the present invention provides an antiviral composition for coronavirus containing an extract of Kwak Hyangjeonggi acid as an active ingredient.
또한, 본 발명은 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 치료용 약학 조성물을 제공한다. In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of coronavirus infection containing Kwakhyangjeonggisan extract as an active ingredient.
또한, 본 발명은 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 건강기능식품 조성물을 제공한다. In addition, the present invention provides a health functional food composition for preventing or improving coronavirus infection containing Kwak Hyangjeonggi acid extract as an active ingredient.
또한, 본 발명은 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 의약외품 조성물을 제공한다. In addition, the present invention provides a quasi-drug composition for preventing or improving coronavirus infection, comprising an extract of Kwakhyangjeonggi acid as an active ingredient.
또한, 본 발명은 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 화장료 조성물을 제공한다. In addition, the present invention provides a cosmetic composition for preventing or improving coronavirus infection containing Kwak Hyangjeonggi acid extract as an active ingredient.
또한, 본 발명은 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 사료 첨가제를 제공한다.In addition, the present invention provides a feed additive for preventing or improving coronavirus infection containing Kwakhyangjeonggisan extract as an active ingredient.
본 발명은 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방, 개선 또는 치료용 조성물에 관한 것으로, 곽향정기산 추출물은 코로나바이러스 감염으로부터 세포를 보호하고, 바이러스의 증식을 억제하며, 코로나바이러스 감염 동물모델에서 감염에 의한 치사율을 감소시키는 효과가 있다.The present invention relates to a composition for preventing, ameliorating or treating coronavirus infection comprising an extract of Kwak Hyang Jeong Gi Acid as an active ingredient. The extract of Kwak Hyang Jeong Gi Acid protects cells from coronavirus infection, inhibits the proliferation of viruses, and prevents the spread of coronavirus. It is effective in reducing the mortality rate due to infection in animal models of viral infection.
도 1은 곽향정기산 추출물의 SARS-CoV2에 대한 항바이러스 효과를 CPE(Cytopathic effect) 억제 분석으로 확인한 결과이다. (A)는 농도별 곽향정기산 추출물 처리에 따른 SARS-CoV2에 대한 항바이러스 효과를 정량한 결과이고, (B)는 양성 대조군인 렘데시비르 처리에 따른 SARS-CoV2에 대한 항바이러스 효과를 정량한 결과이다. NC는 정상군이고, VC는 SARS-CoV2를 처리한 대조군이다. Figure 1 shows the results of confirming the antiviral effect of Kwak Hyangjeonggi acid extract against SARS-CoV2 through CPE (Cytopathic effect) inhibition analysis. (A) is the result of quantifying the antiviral effect against SARS-CoV2 according to treatment with Gwakhyangjeonggisan extract at each concentration, and (B) is the result of quantifying the antiviral effect against SARS-CoV2 according to treatment with remdesivir, a positive control. This is one result. NC is the normal group, and VC is the control group treated with SARS-CoV2.
도 2는 곽향정기산 추출물의 SARS-CoV2에 대한 바이러스 감염 억제 효과를 확인한 형광사진(A) 및 이를 정량한 결과(B)이다. NC는 정상군이고, VC는 SARS-CoV2를 처리한 대조군이다. Figure 2 is a fluorescence photograph (A) confirming the viral infection inhibition effect of Kwak Hyangjeonggi acid extract on SARS-CoV2 and the result of quantifying it (B). NC is the normal group, and VC is the control group treated with SARS-CoV2.
도 3은 SARS-CoV2 감염 동물모델에서 곽향정기산 추출물 투여에 따른 체중(A), 체온(B) 및 생존률(C)을 확인한 결과이다. Mock은 SARS-CoV2에 감염되지 않은 정상군이고, Control은 SARS-CoV2 감염군이다. Figure 3 shows the results of confirming body weight (A), body temperature (B), and survival rate (C) according to administration of Gwakhyangjeonggisan extract in a SARS-CoV2 infection animal model. Mock is a normal group not infected with SARS-CoV2, and Control is a SARS-CoV2 infected group.
본 발명의 목적을 달성하기 위하여, 본 발명은 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스에 대한 항바이러스용 조성물을 제공한다. In order to achieve the object of the present invention, the present invention provides an antiviral composition for coronavirus containing an extract of Kwak Hyangjeonggi acid as an active ingredient.
상기 코로나바이러스는 제2형 중증급성호흡기증후군 코로나바이러스(SARS-CoV2), 중증급성호흡기증후군 코로나바이러스(SARS CoV) 및 중동 호흡기 증후군(MERS) 코로나바이러스로 이루어진 군에서 선택된 1종 이상인 것일 수 있고, 바람직하게는 제2형 중증급성호흡기증후군 코로나바이러스(SARS-CoV2)인 것이지만, 이에 한정하는 것은 아니다. The coronavirus may be one or more types selected from the group consisting of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2), severe acute respiratory syndrome coronavirus (SARS CoV), and Middle East respiratory syndrome (MERS) coronavirus, Preferably, it is type 2 severe acute respiratory syndrome coronavirus (SARS-CoV2), but is not limited thereto.
상기 곽향정기산 추출물의 추출용매는 물, C1~C4의 저급 알코올 또는 이들의 혼합물인 것이 바람직하고, 더 바람직하게는 물인 것이지만, 이에 한정하는 것은 아니다.The extraction solvent of the Kwak Hyangjeonggi acid extract is preferably water, a lower alcohol of C 1 to C 4 or a mixture thereof, more preferably water, but is not limited thereto.
본 발명의 일 구현 예에서, 상기 곽향정기산은 곽향, 자소엽, 백지, 대복피, 복령, 후박, 백출, 진피, 반하, 길경, 자감초, 생강 및 대추의 혼합물일 수 있고, 바람직하게는 150~250 중량부의 곽향, 80~170 중량부의 자소엽, 50~80 중량부의 백지, 50~80 중량부의 대복피, 50~80 중량부의 복령, 50~80 중량부의 후박, 50~80 중량부의 백출, 50~80 중량부의 진피, 50~80 중량부의 반하, 50~80 중량부의 길경, 50~80 중량부의 자감초, 30~70 중량부의 생강 및 50~90 중량부의 대추의 혼합물일 수 있고, 더 바람직하게는 180~200 중량부의 곽향, 115~135 중량부의 자소엽, 55~70 중량부의 백지, 55~70 중량부의 대복피, 55~70 중량부의 복령, 55~70 중량부의 후박, 55~70 중량부의 백출, 55~70 중량부의 진피, 55~70 중량부의 반하, 55~70 중량부의 길경, 55~70 중량부의 자감초, 45~55 중량부의 생강 및 60~75 중량부의 대추의 혼합물이며, 가장 바람직하게는 189.1 중량부의 곽향, 126.0 중량부의 자소엽, 63.0 중량부의 백지, 63.0 중량부의 대복피, 63.0 중량부의 복령, 63.0 중량부의 후박, 63.0 중량부의 백출, 63.0 중량부의 진피, 63.0 중량부의 반하, 63.0 중량부의 길경, 63.0 중량부의 자감초, 50.4 중량부의 생강 및 67.3 중량부의 대추의 혼합물인 것이지만, 이에 제한하는 것은 아니다. In one embodiment of the present invention, the Kwakhyangjeonggisan may be a mixture of Kwakhyang, perilla leaf, Baekji, Daebokpi, Bokryeong, Hubak, Baekchul, Jinpi, Banha, Gilgyeong, Perilla, ginger and jujube, preferably 150 ~250 parts by weight of Gwakhyang, 80~170 parts by weight of perilla leaf, 50~80 parts by weight of Baekji, 50~80 parts by weight of Daebokpi, 50~80 parts by weight of Bokryeong, 50~80 parts by weight of Hubak, 50~80 parts by weight of Baekchul, It may be a mixture of 50 to 80 parts by weight of dermis, 50 to 80 parts by weight of Banha, 50 to 80 parts by weight of Gilt, 50 to 80 parts by weight of perilla root, 30 to 70 parts by weight of ginger and 50 to 90 parts by weight of jujube, and is more preferred. 180-200 parts by weight of Gwakhyang, 115-135 parts by weight of perilla leaves, 55-70 parts by weight of white paper, 55-70 parts by weight of Daebokpi, 55-70 parts by weight of Bokryeong, 55-70 parts by weight of green leaf, 55-70 parts by weight. It is a mixture of 55-70 parts by weight of Baekchul, 55-70 parts by weight of dermis, 55-70 parts by weight of Banha, 55-70 parts by weight of Gilgeung, 55-70 parts by weight of perilla root, 45-55 parts by weight of ginger, and 60-75 parts by weight of jujube. Preferably, 189.1 parts by weight of Gwakhyang, 126.0 parts by weight of perilla leaf, 63.0 parts by weight of Baekji, 63.0 parts by weight of Daebokpi, 63.0 parts by weight of Bokryeong, 63.0 parts by weight of Hubak, 63.0 parts by weight of Baekchul, 63.0 parts by weight of dermis, 63.0 parts by weight of Banha, It is a mixture of 63.0 parts by weight of apricot root, 63.0 parts by weight of perilla root, 50.4 parts by weight of ginger, and 67.3 parts by weight of jujube, but is not limited thereto.
본 발명의 곽향정기산 추출물은 제2형 중증급성호흡기증후군 코로나바이러스의 증식을 억제하는 효과가 있다.The extract of Kwak Hyangjeonggi acid of the present invention has the effect of inhibiting the proliferation of type 2 severe acute respiratory syndrome coronavirus.
또한, 본 발명은 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 치료용 약학 조성물을 제공한다. In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of coronavirus infection containing Kwakhyangjeonggisan extract as an active ingredient.
본 발명에 따른 상기 약학 조성물은 각각 통상의 방법에 따라 캡슐제, 산제, 과립제, 정제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. The pharmaceutical composition according to the present invention can be formulated and used in the form of oral dosage forms such as capsules, powders, granules, tablets, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions according to conventional methods. You can.
본 발명에 따른 상기 약학 조성물은 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 더 포함할 수 있다. The pharmaceutical composition according to the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent.
본 발명의 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 포함한 다양한 화합물 혹은 혼합물을 들 수 있다. Carriers, excipients and diluents that may be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate. , cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 약학 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트, 수크로스 또는 락토오스, 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당하는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔, 마크로골, 트윈 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. in the pharmaceutical composition. It is prepared by mixing. Additionally, in addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, oral solutions, emulsions, syrups, etc. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. . Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, wethepsol, macrogol, Tween 61, cacao, laurin, glycerogelatin, etc. can be used.
본 발명의 약학 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. The appropriate dosage of the pharmaceutical composition of the present invention may be prescribed in various ways depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity. You can.
본 발명의 약학 조성물은 경구 또는 비경구로 투여할 수 있으며, 비경구투여의 경우, 피부에 국소적으로 도포, 정맥 내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등으로 투여할 수 있다.The pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, it can be administered topically on the skin, intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc.
또한, 본 발명은 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 건강기능식품 조성물을 제공한다. In addition, the present invention provides a health functional food composition for preventing or improving coronavirus infection containing Kwak Hyangjeonggi acid extract as an active ingredient.
상기 조성물은 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽 및 음료 중에서 선택된 어느 하나의 제형으로 제조될 수 있지만, 이에 한정하는 것은 아니다. The composition may be manufactured in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup, and beverage, but is not limited thereto.
본 발명의 건강기능식품 조성물을 식품첨가물로 사용하는 경우, 상기 건강기능식품 조성물을 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 양은 그의 사용 목적(예방 또는 개선)에 따라 적절하게 사용될 수 있다. 일반적으로, 식품 또는 음료의 제조시 본 발명의 건강기능식품 조성물은 총 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나 건강을 목적으로 하는 장기간의 섭취인 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로 사용될 수 있다.When using the health functional food composition of the present invention as a food additive, the health functional food composition may be added as is or used together with other foods or food ingredients, and may be used appropriately according to conventional methods. The amount of active ingredient can be appropriately used depending on the purpose of use (prevention or improvement). Generally, when manufacturing a food or beverage, the health functional food composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the total raw materials. However, in the case of long-term intake for health purposes, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
상기 건강기능식품의 종류에 특별한 제한은 없다. 상기 건강기능식품 조성물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There are no particular restrictions on the types of health functional foods. Examples of foods to which the health functional food composition can be added include meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, and tea. There are drinks, alcoholic beverages, and vitamin complexes, and it includes all health foods in the conventional sense.
또한, 본 발명의 건강기능식품 조성물은 식품, 특히 기능성 식품으로 제조될 수 있다. 본 발명의 기능성 식품은 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소 및 조미제를 포함한다. 예컨대, 드링크제로 제조되는 경우에는 유효성분 이외에 천연 탄수화물 또는 향미제를 추가 성분으로서 포함할 수 있다. 상기 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등), 디사카라이드(예컨대, 말토스, 수크로스 등), 올리고당, 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등) 또는 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)인 것이 바람직하다. 상기 향미제는 천연 향미제(예컨대, 타우마틴, 스테비아 추출물 등)와 합성 향미제(예컨대, 사카린, 아스파르탐 등)를 이용할 수 있다.Additionally, the health functional food composition of the present invention can be manufactured into food, especially functional food. The functional food of the present invention includes ingredients commonly added during food production, and includes, for example, proteins, carbohydrates, fats, nutrients and seasonings. For example, when manufactured as a drink, natural carbohydrates or flavoring agents may be included as additional ingredients in addition to the active ingredient. The natural carbohydrates include monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g., dextrins, cyclodextrins, etc.), or sugar alcohols (e.g., For example, xylitol, sorbitol, erythritol, etc.) is preferable. The flavoring agent may be a natural flavoring agent (e.g., thaumatin, stevia extract, etc.) or a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).
상기 건강기능식품 조성물 이외에 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다. 이러한 상기 첨가되는 성분의 비율은 크게 중요하진 않지만 본 발명의 건강기능식품 조성물 100 중량부에 대하여, 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above health functional food composition, various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonic acid. It may further contain carbonating agents used in beverages. The ratio of the ingredients added is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food composition of the present invention.
또한, 본 발명은 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 의약외품 조성물을 제공한다. In addition, the present invention provides a quasi-drug composition for preventing or improving coronavirus infection, comprising an extract of Kwakhyangjeonggi acid as an active ingredient.
상기 의약외품은 피부외용제 및 개인위생용품을 포함할 수 있다. 예를 들어, 소독청결제, 샤워폼, 가그린, 물티슈, 세제비누, 핸드워시, 또는 연고제일 수 있으나 이에 제한되지는 않는다.The quasi-drugs may include external skin preparations and personal hygiene products. For example, it may be a disinfectant cleaner, shower foam, garnish, wet tissue, detergent soap, hand wash, or ointment, but is not limited thereto.
본 발명에 따른 상기 의약외품 조성물을 의약외품 첨가물로 사용할 경우, 상기 조성물을 그대로 첨가하거나 다른 의약외품 또는 의약외품 성분과 함께 사용 할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효성분의 혼합량은 사용 목적에 따라 적합하게 결정될 수 있다.When using the quasi-drug composition according to the present invention as a quasi-drug additive, the composition can be added as is or used with other quasi-drugs or quasi-drug components, and can be used appropriately according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use.
본 발명의 의약외품 조성물은 일 예로, 일반적인 유화 제형 및 가용화 제형의 형태로 제조된 것일 수 있다. 예를 들어, 로션 등과 같은 유액, 크림, 연고, 스프레이, 오일젤, 젤, 오일, 에어로졸과 같은 제형을 가질 수 있으나, 본 발명의 코로나바이러스 감염증의 예방 또는 개선 효과를 나타내는 것이라면 제한되지 않고 사용할 수 있다. For example, the quasi-drug composition of the present invention may be manufactured in the form of a general emulsified formulation or solubilized formulation. For example, it may have a formulation such as lotion, cream, ointment, spray, oil gel, gel, oil, or aerosol, but can be used without limitation as long as it shows the effect of preventing or improving the coronavirus infection of the present invention. there is.
또한, 상기 의약외품 조성물은 각각의 제형에 일반적으로 의약외품 조성물에 배합되는 유분, 물, 계면활성제, 보습제, 탄소수 1 내지 4의 저급 알코올, 증점제, 킬레이트제, 색소, 방부제 또는 향료 등을 필요에 따라 적절히 배합하여 사용할 수 있다.In addition, the quasi-drug composition contains oil, water, surfactants, moisturizers, lower alcohols with 1 to 4 carbon atoms, thickeners, chelating agents, colorants, preservatives or fragrances, etc., which are generally mixed in quasi-drug compositions, as appropriate for each dosage form. Can be used in combination.
또한, 본 발명은 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 화장료 조성물을 제공한다. In addition, the present invention provides a cosmetic composition for preventing or improving coronavirus infection containing Kwak Hyangjeonggi acid extract as an active ingredient.
본 발명의 화장료 조성물은 상기 추출물 이외에 화장료 조성물에 통상적으로 이용되는 성분들이 포함되며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.In addition to the extract, the cosmetic composition of the present invention includes ingredients commonly used in cosmetic compositions, such as antioxidants, stabilizers, solubilizers, vitamins, conventional auxiliaries such as pigments and fragrances, and carriers.
본 발명의 화장료 조성물은 당 업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수(스킨), 영양 화장수(밀크로션), 영양 크림, 맛사지 크림, 에센스, 아이크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 샴푸, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The cosmetic composition of the present invention can be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing products. , oil, powder foundation, emulsion foundation, wax foundation, spray, etc., but is not limited thereto. More specifically, it can be manufactured in the form of flexible lotion (skin), nourishing lotion (milk lotion), nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, shampoo, pack, spray or powder. You can.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라가칸타, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacantha, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier ingredients. It can be.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder can be used as the carrier ingredient. In particular, when the formulation is a spray, chlorofluorohydrocarbon and propane may be used as carrier ingredients. /May contain propellants such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizing agent, or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 , 3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라가칸타 등이 이용될 수 있다.When the formulation of the present invention is a suspension, the carrier ingredients include water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, and microcrystals. Cellulose, aluminum metahydroxide, bentonite, agar or tragacantha can be used.
본 발명의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing agent, the carrier ingredients include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, and fatty acid amide. Ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, or ethoxylated glycerol fatty acid ester can be used.
또한, 본 발명은 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 사료 첨가제를 제공한다. In addition, the present invention provides a feed additive for preventing or improving coronavirus infection containing Kwakhyangjeonggisan extract as an active ingredient.
본 발명의 사료 첨가제는 사료관리법상의 보조사료에 해당한다. 본 발명에서 용어 '사료'는 동물이 먹고, 섭취하며, 소화시키기 위한 또는 이에 적당한 임의의 천연 또는 인공 규정식, 한끼식 등 또는 상기 한끼식의 성분을 의미할 수 있다. 상기 사료의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용되는 사료를 사용할 수 있다. 상기 사료의 비제한적인 예로는, 곡물류, 근과류, 식품 가공 부산물류, 조류, 섬유질류, 제약 부산물류, 유지류, 전분류, 박류 또는 곡물 부산물류 등과 같은 식물성 사료; 단백질류, 무기물류, 유지류, 광물성류, 유지류, 단세포 단백질류, 동물성 플랑크톤류 또는 음식물 등과 같은 동물성 사료를 들 수 있다. 이들은 단독으로 사용되거나 2종 이상을 혼합하여 사용될 수 있다.The feed additive of the present invention corresponds to supplementary feed under the Feed Management Act. In the present invention, the term 'feed' may mean any natural or artificial diet, meal, etc., or a component of the meal, for or suitable for eating, ingestion, and digestion by animals. The type of feed is not particularly limited, and feed commonly used in the art can be used. Non-limiting examples of the feed include plant feeds such as grains, roots and fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils and fats, starches, cucurbits or grain by-products; Examples include animal feeds such as proteins, inorganic substances, fats and oils, minerals, oils and fats, single-cell proteins, zooplanktons or food. These may be used alone or in combination of two or more types.
이하, 제조예 및 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 제조예 및 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다. Hereinafter, the present invention will be described in more detail using manufacturing examples and examples. These manufacturing examples and examples are only for illustrating the present invention in more detail, and it is obvious to those skilled in the art that the scope of the present invention is not limited thereto.
제조예 1. 곽향정기산 추출물의 제조Preparation Example 1. Preparation of Kwakhyangjeonggisan extract
본 발명의 곽향정기산 추출물에 사용된 곽향, 자소엽, 백지, 대복피, 복령, 후박, 백출, 진피, 반하, 길경, 자감초, 생강 및 대추는 동우당제약으로부터 규격품을 구입하였으며, 189.1g의 곽향, 126.0g의 자소엽, 63.0g의 백지, 63.0g의 대복피, 63.0g의 복령, 63.0g의 후박, 63.0g의 백출, 63.0g의 진피, 63.0g의 반하, 63.0g의 길경, 63.0g의 자감초, 50.4g의 생강 및 67.3g의 대추를 혼합한 후, 혼합물 1 중량부에 대하여 5 중량부의 물을 첨가한 다음 100℃에서 4시간 동안 1차 환류추출하였고, 다시 혼합물 1 중량부에 대하여 5 중량부의 물을 첨가한 다음 100℃에서 3시간 동안 2차 환류추출한 후, 거름망(추출포)에 여과한 다음 53㎛ 필터를 통과시킨 후, 통과물을 감압농축 및 동결건조하여 획득하였다. Gwakhyangjeonggisan extract of the present invention used in the extract of Gwakhyangjeonggisan, Gwakhyang, perilla leaf, Baekji, Daebokpi, Bokryeong, Hubak, Baekchul, Jinpi, Banha, Gilgyeong, Perilla perilla, ginger and jujube were purchased as standard products from Dongwoodang Pharmaceutical, weighing 189.1g. of Gwakhyang, 126.0g perilla leaf, 63.0g Baekji, 63.0g Daebokpi, 63.0g Bokryeong, 63.0g Hubak, 63.0g Baekchul, 63.0g dermis, 63.0g Banha, 63.0g Gilgyeong, After mixing 63.0g of perilla, 50.4g of ginger, and 67.3g of jujube, 5 parts by weight of water was added to 1 part by weight of the mixture, and then primary reflux extraction was performed at 100°C for 4 hours, and then 1 weight of the mixture was added again. After adding 5 parts by weight of water, performing secondary reflux extraction at 100°C for 3 hours, filtering through a strainer (extraction cloth), passing through a 53㎛ filter, and obtaining the resultant by concentrating under reduced pressure and freeze-drying. did.
실시예 1. CPE(cytopathic effect) 억제 분석을 통한 곽향정기산 추출물의 항바이러스 활성 확인Example 1. Confirmation of antiviral activity of Gwakhyangjeonggisan extract through CPE (cytopathic effect) inhibition analysis
96웰 플레이트에 Vero E6 세포를 배양한 후, SARS-CoV2를 m.o.i 0.01로 접종하였다. 접종 후, 처리 농도에 맞도록 2%(v/v) FBS 및 1%(v/v) 페니실린-스트렙토마이신이 포함된 DMEM으로 희석하여 준비한 상기 제조예 1의 곽향정기산 추출물을 농도별로 처리한 다음, 3일 동안 배양하였다. 배양 후, 세포 배양액을 제거한 다음 메탄올:아세톤이 1:1 부피비로 혼합된 용액을 처리한 다음 실온에서 10분 동안 고정하였다. 이후, 용액을 제거하고, 0.4%(w/v) 크리스탈 바이올렛(crystal violet)을 각 웰에 첨가한 다음 10분 동안 실온에서 염색한 후, 용액을 모두 제거하고 건조하였다. 건조 후, 메탄올:아세트산을 1:1 부피비로 혼합한 다음 이를 3차 증류수로 5배 희석한 용액을 각 웰에 100㎕씩 첨가한 후 2시간 동안 크리스탈 바이올렛을 추출하였고, 이의 흡광도를 550nm에서 측정하였다. After culturing Vero E6 cells in a 96-well plate, SARS-CoV2 was inoculated at an m.o.i of 0.01. After inoculation, the Kwakhyangjeonggi acid extract of Preparation Example 1 prepared by diluting with DMEM containing 2% (v/v) FBS and 1% (v/v) penicillin-streptomycin to match the treatment concentration was treated according to concentration. Next, it was cultured for 3 days. After incubation, the cell culture medium was removed, and then treated with a 1:1 volume ratio of methanol:acetone and fixed for 10 minutes at room temperature. Afterwards, the solution was removed, 0.4% (w/v) crystal violet was added to each well, and the cells were stained at room temperature for 10 minutes, then all of the solution was removed and dried. After drying, methanol:acetic acid was mixed in a 1:1 volume ratio, and then 100 ㎕ of a 5-fold diluted solution with distilled water was added to each well. Crystal violet was extracted for 2 hours, and its absorbance was measured at 550 nm. did.
그 결과, 도 1에 개시된 바와 같이 본 발명의 곽향정기산 추출물을 처리한 경우, SARS-CoV2의 증식을 억제하였으므로, 본 발명의 곽향정기산 추출물은 SARS-CoV2 바이러스로부터 세포를 보호하고, 바이러스의 증식을 억제하는 항바이러스 효과가 우수하였다. As a result, when treated with the Kwak Hyangjeonggi acid extract of the present invention as shown in Figure 1, the proliferation of SARS-CoV2 was inhibited. Therefore, the Kwakhyangjeonggi acid extract of the present invention protects cells from the SARS-CoV2 virus and kills the virus. The antiviral effect of inhibiting proliferation was excellent.
실시예 2. 곽향정기산 추출물의 바이러스 감염 억제 효과 확인Example 2. Confirmation of the virus infection inhibition effect of Gwakhyangjeonggisan extract
곽향정기산 추출물의 SARS-CoV2 바이러스 감염 억제 효과를 면역형광분석법으로 확인하였다. 구체적으로, Vero E6 세포를 1×104 세포/웰로 96웰 플레이트에 분주하고, 곽향정기산 추출물을 처리한 후, 2%(v/v) FBS 및 1%(v/v) 항생제가 포함된 DMEM으로 1000배 희석한 SARS-CoV2를 처리한 다음 24시간 동안 배양하였다. 배양 후, 4%(v/v) 포름알데히드(formaldehyde) 용액으로 세포를 고정한 다음 2000배 희석한 1차 항체(N-단백질)와 반응시킨 후, 200배 희석한 2차 항체와 반응시켰다. 반응 후, 세포를 형광현미경으로 관찰하였고, 형광강도를 분석하였다.The inhibitory effect of Kwakhyangjeonggisan extract on SARS-CoV2 virus infection was confirmed using immunofluorescence analysis. Specifically, Vero E6 cells were distributed in a 96 -well plate at 1 SARS-CoV2 diluted 1000 times with DMEM was treated and then cultured for 24 hours. After incubation, the cells were fixed with a 4% (v/v) formaldehyde solution, reacted with a primary antibody (N-protein) diluted 2000 times, and then reacted with a secondary antibody diluted 200 times. After the reaction, the cells were observed under a fluorescence microscope, and the fluorescence intensity was analyzed.
그 결과, 도 2에 개시된 바와 같이 곽향정기산 추출물 처리에 의해 SARS-CoV2 바이러스의 세포 내 감염이 효과적으로 억제되었다.As a result, as shown in Figure 2, intracellular infection of the SARS-CoV2 virus was effectively inhibited by treatment with Kwak Hyangjeonggi acid extract.
실시예 3. SARS-CoV2 감염 동물모델에서 곽향정기산 추출물의 효능 평가Example 3. Evaluation of the efficacy of Gwakhyangjeonggisan extract in a SARS-CoV2 infection animal model
hACE2 형질전환 마우스 모델에서 SARS-CoV2 감염에 대한 억제 효능을 평가하기 위하여, SARS-CoV2 감염시키기 2일 전부터 사망하는 날까지 3차 증류수에 녹인 곽향정기산 추출물을 1일 1회 경구 투여하였다. 감염 당일(0일째) 본 발명의 곽향정기산 추출물을 경구 투여하고 1시간 후, SARS-CoV2를 2,000pfu/mouse로 비강 접종하여 감염시켰고(20㎕/mouse), 실험 종료일 까지 매일 체중 및 체온을 측정하였다.To evaluate the inhibitory efficacy against SARS-CoV2 infection in the hACE2 transgenic mouse model, Kwakhyangjeongkisan extract dissolved in distilled water was orally administered once a day from 2 days before SARS-CoV2 infection until the day of death. On the day of infection (day 0), the extract of Kwakhyangjeonggi of the present invention was orally administered, and 1 hour later, SARS-CoV2 was inoculated intranasally at 2,000 pfu/mouse and infected (20㎕/mouse), and body weight and body temperature were measured every day until the end of the experiment. Measured.
그 결과, 도 3에 개시된 바와 같이 본 발명의 곽향정기산 추출물 투여군의 체중은 6일째 이후, SARS-CoV2 감염군보다 약간 증가한 수준으로 나타났으며, 체온은 SARS-CoV2 감염군의 경우, 6일째 급격하게 체온이 감소하였으나, 본 발명의 곽향정기산 추출물 투여군은 정상군과 유사한 수준으로 체온을 유지하고 있었고, SARS-CoV2 감염군의 10일 째 생존율은 급격하게 감소하였으나, 본 발명의 곽향정기산 추출물 투여군의 생존율은 약 60% 수준을 유지하였다. 따라서 본 발명의 곽향정기산 추출물은 중증 SARS-CoV2 감염군의 치사율을 낮출 수 있는 것으로 판단하였다.As a result, as shown in Figure 3, the body weight of the group administered the Kwak Hyangjeonggi acid extract of the present invention was slightly increased compared to the SARS-CoV2 infection group after the 6th day, and the body temperature of the SARS-CoV2 infection group was 6 days. Although the body temperature rapidly decreased, the group administered the Kwak Hyang Jeong-ki acid extract of the present invention maintained body temperature at a level similar to that of the normal group, and the survival rate of the SARS-CoV2 infection group on day 10 decreased sharply, but the The survival rate of the extract administered group was maintained at about 60%. Therefore, it was determined that the Kwak Hyangjeonggi acid extract of the present invention can reduce the mortality rate of the severe SARS-CoV2 infection group.

Claims (12)

  1. 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스에 대한 항바이러스용 조성물.An antiviral composition for coronavirus containing Kwakhyangjeonggisan extract as an active ingredient.
  2. 제1항에 있어서, 상기 코로나바이러스는 제2형 중증급성호흡기증후군 코로나바이러스(SARS-CoV2)인 것을 특징으로 하는 코로나바이러스에 대한 항바이러스용 조성물.The composition for antiviral use against coronavirus according to claim 1, wherein the coronavirus is type 2 severe acute respiratory syndrome coronavirus (SARS-CoV2).
  3. 제1항에 있어서, 상기 곽향정기산 추출물의 추출용매는 물, C1~C4의 저급 알코올 또는 이들의 혼합물인 것을 특징으로 하는 코로나바이러스에 대한 항바이러스용 조성물.The antiviral composition for coronavirus according to claim 1, wherein the extraction solvent of the Kwak Hyangjeonggi acid extract is water, a lower alcohol of C 1 to C 4 , or a mixture thereof.
  4. 제1항에 있어서, 상기 곽향정기산은 곽향, 자소엽, 백지, 대복피, 복령, 후박, 백출, 진피, 반하, 길경, 자감초, 생강 및 대추의 혼합물인 것을 특징으로 하는 코로나바이러스에 대한 항바이러스용 조성물.The anti-coronavirus agent of claim 1, wherein the Kwakhyangjeonggisan is a mixture of Gwakhyang, perilla leaf, Baekji, Daebokpi, Bokryeong, Hubak, Baekchul, Jinpi, Banha, Gilgyeong, Perilla, Ginger and Jujube. Composition for viruses.
  5. 제4항에 있어서, 상기 혼합물은 150~250 중량부의 곽향, 80~170 중량부의 자소엽, 50~80 중량부의 백지, 50~80 중량부의 대복피, 50~80 중량부의 복령, 50~80 중량부의 후박, 50~80 중량부의 백출, 50~80 중량부의 진피, 50~80 중량부의 반하, 50~80 중량부의 길경, 50~80 중량부의 자감초, 30~70 중량부의 생강 및 50~90 중량부의 대추로 이루어진 것을 특징으로 하는 코로나바이러스에 대한 항바이러스용 조성물.The method of claim 4, wherein the mixture is 150 to 250 parts by weight of Gwakhyang, 80 to 170 parts by weight of perilla leaf, 50 to 80 parts by weight of white paper, 50 to 80 parts by weight of Daebokpi, 50 to 80 parts by weight of Bokryeong, 50 to 80 parts by weight. 100 parts by weight, 50-80 parts by weight of Baekchul, 50-80 parts by weight of dermis, 50-80 parts by weight of Banha, 50-80 parts by weight of Gilgeung, 50-80 parts by weight of perilla root, 30-70 parts by weight of ginger and 50-90 parts by weight. An antiviral composition against coronavirus, characterized in that it consists of jujube.
  6. 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 치료용 약학 조성물.A pharmaceutical composition for the prevention or treatment of coronavirus infection containing extract of Kwakhyangjeonggisan as an active ingredient.
  7. 제6항에 있어서, 상기 곽향정기산 추출물 이외에 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 더 포함하는 것을 특징으로 하는 코로나바이러스 감염증의 예방 또는 치료용 약학 조성물.The pharmaceutical composition for preventing or treating coronavirus infection according to claim 6, further comprising a pharmaceutically acceptable carrier, excipient, or diluent in addition to the Kwak Hyangjeonggi acid extract.
  8. 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 건강기능식품 조성물.A health functional food composition for preventing or improving coronavirus infection containing Kwakhyangjeonggisan extract as an active ingredient.
  9. 제8항에 있어서, 상기 조성물은 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽 및 음료 중에서 선택된 어느 하나의 제형으로 제조되는 것을 특징으로 하는 코로나바이러스 감염증의 예방 또는 개선용 건강기능식품 조성물.The health functional food composition for preventing or improving coronavirus infection according to claim 8, wherein the composition is manufactured in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup, and beverage.
  10. 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 의약외품 조성물.A quasi-drug composition for preventing or improving coronavirus infection containing Kwakhyangjeonggisan extract as an active ingredient.
  11. 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 화장료 조성물.A cosmetic composition for preventing or improving coronavirus infection containing extract of Kwakhyangjeonggisan as an active ingredient.
  12. 곽향정기산 추출물을 유효성분으로 포함하는 코로나바이러스 감염증의 예방 또는 개선용 사료 첨가제.A feed additive for preventing or improving coronavirus infection containing Kwakhyangjeonggisan extract as an active ingredient.
PCT/KR2023/005308 2022-04-20 2023-04-19 Composition for preventing, alleviating, or treating coronavirus infection, containing medicinal herb complex extract as active ingredient WO2023204603A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2022-0048912 2022-04-20
KR1020220048912A KR102527037B1 (en) 2022-04-20 2022-04-20 Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine mixture extract as effective component

Publications (1)

Publication Number Publication Date
WO2023204603A1 true WO2023204603A1 (en) 2023-10-26

Family

ID=86387545

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/005308 WO2023204603A1 (en) 2022-04-20 2023-04-19 Composition for preventing, alleviating, or treating coronavirus infection, containing medicinal herb complex extract as active ingredient

Country Status (2)

Country Link
KR (1) KR102527037B1 (en)
WO (1) WO2023204603A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210112570A (en) * 2020-03-05 2021-09-15 남종현 Tea composition for preventing, improving or treating respiratory disease and pharmaceutical composition including the same
KR20220018919A (en) * 2020-08-07 2022-02-15 기초과학연구원 Pharmaceutical composition for the prevention and treatment of Envelopled viruses comprising taining Platycodon grandiflorus root extracts
KR20220044082A (en) * 2020-09-28 2022-04-06 한국 한의학 연구원 Composition for preventing or treating corona virus comprising herbal mixing extracts

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210112570A (en) * 2020-03-05 2021-09-15 남종현 Tea composition for preventing, improving or treating respiratory disease and pharmaceutical composition including the same
KR20220018919A (en) * 2020-08-07 2022-02-15 기초과학연구원 Pharmaceutical composition for the prevention and treatment of Envelopled viruses comprising taining Platycodon grandiflorus root extracts
KR20220044082A (en) * 2020-09-28 2022-04-06 한국 한의학 연구원 Composition for preventing or treating corona virus comprising herbal mixing extracts

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KANG BO-HYUNG, CHOI YOU-KYOUNG, JEON CHAN-YONG, YANG SEUNG-BO: "The Effects of Qingfei Paidu Decoction on Coronavirus Disease-19: A Narrative Review", THE KOREAN SOCIETY FOR ORIENTAL INTERNAL MEDICINE, KOREAN INTELLECTUAL PROPERTY OFFICE, vol. 41, no. 3, 30 June 2020 (2020-06-30), pages 424 - 433, XP093101027, ISSN: 1226-9174, DOI: 10.22246/jikm.2020.41.3.424 *
LEE JONG-HOON: "Corona treatment herbal medicine 6 Kwakhyangjeonggisan prescription explanation: Naver blog", BLOG DR. JONG-HOON LEE, 25 January 2022 (2022-01-25), XP093100694, Retrieved from the Internet <URL:https://m.blog.naver.com/yijonghoon/222631029583> [retrieved on 20231113] *

Also Published As

Publication number Publication date
KR102527037B1 (en) 2023-05-02

Similar Documents

Publication Publication Date Title
WO2020013610A1 (en) Composition for preventing, alleviating or treating allergic skin diseases, containing, as active ingredient, extract of gardenia fruits from which pigments are removed
WO2023249392A1 (en) Composition for prevention, amelioration or treatment of coronavirus infection, comprising medicinal herb extract as active ingredient
WO2023249393A1 (en) Composition for prevention, amelioration or treatment of coronavirus infection comprising medicinal herb extract as active ingredient
WO2011055931A2 (en) Composition for preventing or treating diseases caused by influenza viruses
KR102187951B1 (en) Pharmaceutical composition for the treatment of Epstein-Barr virus-positive gastric cancer, comprising an extract of Ganoderma lucidum and quercetin as an active ingredient
KR102540814B1 (en) Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component
WO2023204603A1 (en) Composition for preventing, alleviating, or treating coronavirus infection, containing medicinal herb complex extract as active ingredient
EP0297547A2 (en) Use of hydrolyzable tannins for treatement and prophylaxis of AIDS
WO2023204602A1 (en) Composition, for preventing, ameliorating, or treating coronavirus infections, comprising herbal medicine extract as active ingredient
WO2023200289A1 (en) Composition for prevention, amelioration or treatment of coronavirus infection comprising medicinal herb extract as active ingredient
KR102578871B1 (en) Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component
KR102676865B1 (en) Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component
KR102540384B1 (en) Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component
KR102526308B1 (en) Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component
KR102529571B1 (en) Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component
KR102533344B1 (en) Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component
KR102524075B1 (en) Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component
KR102506856B1 (en) Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component
KR102512522B1 (en) Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component
KR102524078B1 (en) Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component
KR102499066B1 (en) Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component
KR102532944B1 (en) Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine mixture extract as effective component
KR102546110B1 (en) Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component
KR102524083B1 (en) Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component
KR102526488B1 (en) Composition for preventing, ameliorating or treating coronavirus infectious disease comprising herbal medicine extract as effective component

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23792177

Country of ref document: EP

Kind code of ref document: A1